The Impact of Changed Strategies for Patients with Cholangiocarcinoma in This Millenium

摘要

Background.Cholangiocarcinoma is a cancer with a poor prognosis. In this millennium there are new diagnostic and therapeutic strategies for these patients.Aim.The aim of this study was to find if these changes influenced survival of individuals with proximal cholangiocarcinoma.Material.627 individuals with a diagnosis of cholangiocarcinoma (not including distal common duct cancer) during the period from 2000 to 2011 were registered in Sweden’s Western Region. The material was divided into three consecutive time periods.Results.The overall survival curves for individuals with cholangiocarcinoma improved over the three time periods(n=627) (P=0.0013). Median survival increased from 2.6 months in the first period (2000–2003) to 3.6 months in the final four years (2008–2011). Patients with perihilar cholangiocarcinoma (PHC) had longer median survival than those with intrahepatic cholangiocarcinoma (IHC): 6.8 versus 3.2 months(P=0.0003). An improvement in the survival curves over time was seen for those with IHC(P=0.034)but not for patients with PHC(P=0.38). Nine percent of the patients with IHC had potential curative surgical therapy. The three-year survival rate after liver resection for patients with IHC was 35% and 60% after liver transplantation. Among patients with PHC, 15.3% had potential curative bile duct resection with a concomitant liver resection and 6.1% bile duct resection alone. The three-year survival rate for these two groups was 32% and 20%, respectively.Conclusion.Overall survival for individuals with PHC was better than for those with IHC. Over time survival in IHC patients improved but not in those with PHC.